Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil, and concomitant radiotherapy for poor-prognosis head and neck cancer.
Concomitant chemoradiotherapy holds promise in the therapy of advanced head and neck cancer. We have previously reported on the combination of 5-fluorouracil, hydroxyurea, and concomitant chemoradiotherapy administered on an alternate-week basis. In this ongoing study, we are testing the feasibility of adding continuous-infusion paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) to this combination. Background information and early clinical data are presented.
Vokes
E E
EE
Department of Medicine, University of Chicago, IL, USA.
Stupp
R
R
Haraf
D
D
Moran
W
W
Malone
D
D
Wenig
B
B
Sweeney
P
P
Weichselbaum
R R
RR
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005472:Fluorouracil / Q000008:administration & dosage; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D007262:Infusions, Intravenous; D017239:Paclitaxel / Q000008:administration & dosage
D017239:Paclitaxel; D005472:Fluorouracil; D006918:Hydroxyurea